Payment overview · 2025
General Payments
$93.49
4 reported records · 3 companies
Healthcare provider profile · identity verified
William E Reynolds, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ENTERPRISE, AL · NPI 1134178668
Verified facts
What the public records show
CMS Open Payments records show William E Reynolds, MD received $93.49 in general payments during 2025 across 4 reported records.
Amgen Inc. accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.71 | 37.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.81 | 36.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.97 | 26.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $93.49 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.71 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.81 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 822 | 226 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 599 | 96 |
| Gabapentin | Gabapentin | 540 | 118 |
| Tramadol Hcl | Tramadol Hcl | 502 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 422 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 115 |
| Meloxicam | Meloxicam | 379 | 102 |
| Lisinopril | Lisinopril | 369 | 109 |
| Metformin Hcl | Metformin Hcl | 363 | 96 |
| Omeprazole | Omeprazole | 359 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 102 |
| Potassium Chloride | Potassium Chloride | 293 | 87 |
| Losartan Potassium | Losartan Potassium | 291 | 93 |
| Simvastatin | Simvastatin | 286 | 75 |
| Alprazolam | Alprazolam | 262 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 67 |
| Metformin Hcl Er | Metformin Hcl | 210 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 64 |
| Temazepam | Temazepam | 207 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 63 |
| Sertraline Hcl | Sertraline Hcl | 204 | 50 |
| Furosemide | Furosemide | 202 | 65 |
| Montelukast Sodium | Montelukast Sodium | 200 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 197 | 28 |
| Trazodone Hcl | Trazodone Hcl | 195 | 60 |
| Glimepiride | Glimepiride | 187 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 179 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 167 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 46 |
| Allopurinol | Allopurinol | 163 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 41 |
| Jardiance | Empagliflozin | 156 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 31 |
| Eliquis | Apixaban | 149 | 27 |
| Prednisone | Prednisone | 146 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 32 |
| Clonazepam | Clonazepam | 130 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 45 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 126 | 32 |
| Buspirone Hcl | Buspirone Hcl | 125 | 29 |
| Ozempic | Semaglutide | 123 | 19 |
| Mounjaro | Tirzepatide | 110 | 18 |
| Carvedilol | Carvedilol | 107 | 31 |
| Celecoxib | Celecoxib | 107 | 31 |
| Meclizine Hcl | Meclizine Hcl | 107 | 35 |
| Spironolactone | Spironolactone | 107 | 32 |
| Xarelto | Rivaroxaban | 107 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 97 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 30 |
| Estradiol | Estradiol | 93 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 19 |
| Azithromycin | Azithromycin | 84 | 68 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 23 |
| Pregabalin | Pregabalin | 79 | 21 |
| Ibuprofen | Ibuprofen | 78 | 31 |
| Cefuroxime | Cefuroxime Axetil | 77 | 69 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 18 |
| Diazepam | Diazepam | 75 | 20 |
| Januvia | Sitagliptin Phosphate | 73 | 16 |
| Methocarbamol | Methocarbamol | 73 | 28 |
| Glipizide | Glipizide | 71 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 69 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 13 |
| Alendronate Sodium | Alendronate Sodium | 60 | 20 |
| Donepezil Hcl | Donepezil Hcl | 60 | 19 |
| Famotidine | Famotidine | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 15 |
| Lorazepam | Lorazepam | 54 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 51 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 51 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 13 |
| Clonidine Hcl | Clonidine Hcl | 49 | 12 |
| Atenolol | Atenolol | 48 | 13 |
| Mirtazapine | Mirtazapine | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 23 |
| Memantine Hcl | Memantine Hcl | 43 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Naproxen | Naproxen | 41 | 19 |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 23 |
| Valsartan | Valsartan | 40 | 13 |
| Bumetanide | Bumetanide | 39 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 11 |
| Primidone | Primidone | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 21 |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 11 |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 22 |
| Mupirocin | Mupirocin | 23 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 16 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $93.49 · 4 records | Amgen Inc. | EVENITY, TRELEGY ELLIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error